Biomere is a growing preclinical contract research organization (CRO) based in the greater Boston area (Worcester MA). The facility includes multiple floors of vivarium space for rodents and large animals, and dedicated laboratory space for sample management and analysis.
The company was established in 1996 as a spin out from the University of Massachusetts Medical School and moved into the current facility in 2015. Since then, we have expanded floor-by-floor to the current 100,000 sq. ft. space that includes vivarium, laboratory and office spaces. In parallel, we have grown to over 150 employees. Biomere is AAALAC accredited, OLAW Assured, DEA Licensed, and USDA Registered.
JOINN Laboratories, a public CRO based in China acquired Biomere in 2019, extending Biomere’s preclinical drug development capabilities globally. The combination of JOINN and Biomere’s portfolios offer non-GLP studies in the US and GLP toxicology programs in China. JOINN Laboratories has multiple facilities in Suzhou, Beijing, Wuzhou, Chongqing and Guangzhou and has vivarium spaces and laboratory in Richmond, California.
Our core areas of expertise are PK/PD and ADME studies in rodent and large animal models, including primates, early efficacy and toxicology. Our team has expertise in specialty dosing and downstream analysis in several areas including CNS, gene therapy, ocular and custom surgical models. We have expertise in rederiving, breeding and developing genetically modified rodent colonies to ensure study-ready cohorts for preclinical studies.
